• The LIAISON SARS- CoV-2 S1/S2 IgG assay should not be used to diagnose or exclude acute infection and should not be used as the sole basis for treatment or patient management decisions. Direct COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2 1,2,3.Since December of 2019, COVID-19 has spread worldwide causing nearly 81 million infections and over 1.7 million 2.1. Sample Collection. Data from 579 participants were collected between January and April 2021. The minimum numbers of participants necessary for this study were 162 women and 162 children, based on the equation suggested by Charan and Biswas [], using alpha = 0.05, an expected proportion of 30% positive SARS-CoV-2 anti-spike (anti-S) IgG cases, and a precision of 5%. Serum samples were processed and analyzed for SARS-CoV-2 IgG antibodies and anti N-protein IgG levels using an ELISA kit for IgG by Epitope Diagnostics 16 according to manufacturer’s protocol A previous study validated five commercial SARS-CoV-2 IgG immunoassays on a cohort of recovered patients previously infected with SARS-CoV-2 (n = 363, 141–176 days after disease onset) and reported the lowest sensitivity of 53.71% for Abbott (anti-N), and the highest sensitivity of 93.11% for Roche (anti-N). The sensitivities of two anti-S1 The SARS-CoV-2 virus is a single-stranded RNA virus belonging to the Betacoronavirus family. It has four key structural proteins of which the nucleocapsid protein or N protein is one. .

anti sars cov 2 igg kuantitatif